The Design and Analysis of Multisite Effectiveness Trials: A Decade of Progress in the National Drug Abuse Clinical Trials Network

REFERENCES

• Rounsaville BJ, Carroll KM, Onken LS. NIDA’s stage model of behavioral therapies research: Getting started and moving on from Stage I. Clin Psychol Sci Pract 2001; 8:133–142.
   Web of Science ®Google Scholar
• Brigham GS, Feaster DJ, Wakim PG, Dempsey CL. Choosing a control group in effectiveness trials of behavioral drug abuse treatments. J Subst Abuse Treat 2009; 37:388–397.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine. Bridging the Gap Between Practice and Research: Forging Partnerships with Community-Based Drug and Alcohol Treatment. Washington, DC: National Academy Press, 1998.
   Google Scholar
• Nunes EV, Ball S, Booth R, Brigham G, Calsyn DA,Carroll K, Feaster DJ, Hien D, Hubbard RL, Ling W, Petry NM, Rotrosen J, Selzer J, Stitzer M, Tross S, Wakim P, Winhusen T, Woody G. Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: Have we chosen the best designs? J Subst Abuse Treat 2010; 38(Suppl. 1):S97–S112.
   PubMed Web of Science ®Google Scholar
• Carroll K, Ball SA, Jackson R, Martino S, Petry NM, Stitzer ML, Wells EA, Weiss RD. Ten Take Home Lessons from the First 10 Years of the CTN and 10 Recommendations for the Future. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):275–282.
   PubMed Web of Science ®Google Scholar
• Tross S, Campbell AN, Calsyn DA, Metsch LR, Sorensen JL, Shoptaw S, Haynes L, Woody G, Malow RM, Brown LS Jr, Feaster DJ, Booth RE, Mandler RN, Masson C, Holmes BW, Colfax G, Brooks AJ, Hien DA, Schackman BR, Korthuis T, Miele GM. Clinical Trials Network HIV Special Interest Group. NIDA’s Clinical Trials Network: An opportunity for HIV research in Community Substance Abuse Treatment Programs. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):283–293.
   PubMed Web of Science ®Google Scholar
• Calsyn D, Campbell AN, Tross S, Hatch-Maillette MA. Is monogamy or committed relationship status a marker for low sexual risk among men in substance abuse treatment? Clinical and methodological considerations. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):294–300.
   PubMed Web of Science ®Google Scholar
• Greenfield SF, Rosa C, Putnins SI, Green CA, Brooks AJ, Calsyn DA, Cohen LR, Erickson S, Gordon SM, Haynes L, Killeen T, Miele G, Tross S, Winhusen T. Gender research in the National Institute on Drug Abuse National Treatment Clinical Trials Network: A summary of findings. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):301–312.
   PubMed Web of Science ®Google Scholar
• Back S, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, Hillhouse M, Brady KT, Ling W. Comparative profiles of men and women with opioid dependence: Results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):313–323.
   PubMed Web of Science ®Google Scholar
• Burlew K, Weekes JC, Montgomery L, Feaster DJ, Robbins MS, Rosa CL, Ruglass LM, Venner KL, Wu L. Conducting research with racial/ethnic minorities: Methodological lessons from the NIDA Clinical Trials Network. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):324–332.
   PubMed Web of Science ®Google Scholar
• Thomas LR, Rosa C, Forcehimes A, Donovan DM. Research partnerships between academic institutions and American Indian and Alaska Native tribes and organizations: Effective strategies and lessons learned in a multi-site CTN study. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):333–338.
   PubMed Web of Science ®Google Scholar
• Trivedi M, Greer TL, Potter JS, Grannemann BD, Nunes EV, Rethorst C, Warden D, Ring KM, Somoza E. Determining the primary endpoint for a stimulant abuse trial: Lessons learned from STRIDE. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):339–349.
   PubMed Web of Science ®Google Scholar
• Oden N, VanVeldhuisen PC, Wakim PG, Trivedi MH, Somoza E, Lewis D. Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):350–357.
   PubMed Web of Science ®Google Scholar
• Korte J, Magruder KM, Chiuzan CC, Logan SL, Killeen T, Bandyopadhyay D, Brady KT. Assessing drug use during follow-up: Direct comparison of candidate outcome definitions in pooled analyses of addiction treatment studies. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):358–366.
   PubMed Web of Science ®Google Scholar
• Hu M, Pavlicova M, Nunes EV. Zero-inflated and hurdle models of count data with extra zeros: Examples from an HIV-risk reduction intervention trial. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):367–375.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay D, DeSantis SM, Korte JE, Brady KT. Some considerations for excess zeroes in substance abuse research. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):376–382.
   PubMed Web of Science ®Google Scholar
• Feaster D, Mikulich-Gilbertson S, Brincks AM. Modeling site effects in the design and analysis of multi-site trials. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):383–391.
   PubMed Web of Science ®Google Scholar
• Covey L, Hu M, Green CA, Brigham G, Hurt RD, Adler L, Winhusen T. An exploration of site effects in a multisite trial of OROS-methylphenidate for smokers with attention deficit/hyperactivity disorder. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):392–399.
   PubMed Web of Science ®Google Scholar
• Donovan D, Weiss RD, Gardin J, Lindblad R, Wakim P, Dodd D. Site selection in community-based clinical trials for substance use disorders: Strategies for effective site selection. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):400–407.
   PubMed Web of Science ®Google Scholar
• Donovan D, Daley DC, Brigham GS, Hodgkins CC, Perl HI, Floyd AS. How practice and science are balanced and blended in the NIDA Clinical Trials Network: The bidirectional process in the development of the STAGE-12 protocol as an example. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):408–416.
   PubMed Web of Science ®Google Scholar
• Bogenschutz M, Donovan DM, Adinoff B, Crandall C, Forcehimes AA, Lindblad L, Mandler RN, Oden N, Perl HI, Walker R. Design of NIDA CTN Protocol 0047: Screening, motivational assessment, referral, and treatment in emergency departments (SMART-ED). Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):417–425.
   PubMed Web of Science ®Google Scholar
• Wakim P, Rosa C, Kothari P, Michel ME. Relation of study design to recruitment and retention in CTN trials. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):426–433.
   PubMed Web of Science ®Google Scholar
• Fussell H, Kunkel LE, McCarty D, Lewy CS. Standardized patient walkthroughs in the National Drug Abuse Treatment Clinical Trials Network: Common challenges to protocol implementation. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):434–439.
   PubMed Web of Science ®Google Scholar
• Lindblad R, Campanella M, Styers D, Kothari P, Sparenborg S, Rosa C. Strategies for safety reporting in substance abuse trials. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):440–445.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Pavlicova M, Hu M, Campbell AN, Miele G, Hien D, Klein DF. Baseline matters: The importance of covariation for baseline severity in the analysis of clinical trials. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):446–452.
   PubMed Web of Science ®Google Scholar
• Hillhouse M, Canamar CP, Doraimani G, Thomas C, Hasson A, Ling W. Patient characteristics and buprenorphine dose. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):453–459.
   PubMed Web of Science ®Google Scholar
• Hartzler B, Donovan DM, Huang Z. Rates and influences of alcohol use disorder comorbidity among primary stimulant misusing treatment seekers: Meta-analytic findings across eight NIDA CTN trials. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):460–471.
   PubMed Web of Science ®Google Scholar
• Reid MS, Jiang H, Fallon B, Sonne S, Rinaldi P, Turrigiano E, Arfken C, Robinson J, Rotrosen J, Nunes EV. Smoking cessation treatment among patients in community-based substance abuse rehabilitation programs: Exploring predictors of outcome as clues toward treatment improvement. Am J Drug Alcohol Abuse 2011; 37(5The Clinical Trials Network: A Decade of Progress (Guest Editor: Edward Nunes)):472–478.
   PubMed Web of Science ®Google Scholar